said a group in England has recommended that Tysabri be used in people with highly active relapsing remitting multiple sclerosis.
The recommendation was made by the National Institute for Health and Clinical Excellence, or NICE. Tysabri is the first treatment for MS the group has endorsed.
NICE is an independent organization the provides guidance on how to best maintain good health and to prevent and treat illnesses.
For Biogen and Elan, the NICE decision is the latest step in Tysabri's comeback. The drug was taken off the U.S. market in 2005 after being linked to a potentially deadly brain disease, but last year regulators cleared it for sale, with certain restrictions.